Cargando…
L-Arginine, Nitric Oxide, and Endothelial Dysfunction Underlying Atherosclerotic Cardiovascular Disease (ASCVD)
Autor principal: | Shimabukuro, Michio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564653/ https://www.ncbi.nlm.nih.gov/pubmed/37245961 http://dx.doi.org/10.5551/jat.ED235 |
Ejemplares similares
-
MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker
por: Shimabukuro, Michio
Publicado: (2023) -
SIRT1 and Gender Differences in Atherosclerotic Cardiovascular Disease
por: Shimabukuro, Michio
Publicado: (2020) -
Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD)
por: Parums, Dinah V.
Publicado: (2021) -
Functional Impairment of Endothelial Colony Forming Cells (ECFC) in Patients with Severe Atherosclerotic Cardiovascular Disease (ASCVD)
por: Simoncini, Stéphanie, et al.
Publicado: (2022) -
Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)